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Abstract
Background: Biochemical markers of bone turnover (BTMs), such as the bone alkaline phosphatase (bALP),
procollagen type I N propeptide (PINP), serum cross-linked C-telopeptides of type I collagen (bCTx), and urinary
cross-linked N-telopeptides of type I collagen (NTx), are used to manage therapy monitoring in osteoporotic
patients. This systematic review analyzed the potential of these BMTs in predicting the clinical outcomes in terms of
BMD, t-score, rate of fractures, and adverse events during the therapy setting in postmenopausal osteoporosis.
Methods: All randomized clinical trials (RCTs) reporting data on biomarkers for postmenopausal osteoporosis were
accessed. Only articles reporting quantitative data on the level of biomarkers at baseline and on the outcomes of
interest at the last follow-up were eligible.
Results: A total of 36,706 patients were retrieved. Greater values of bALP were associated with a greater rate of
vertebral (P = 0.001) and non-vertebral fractures (P = 0.0001). Greater values of NTx at baseline were associated with
a greater rate of adverse events at the last follow-up (P = 0.02). Greater values of CTx at baseline were associated
with a greater rate of adverse events leading to discontinuation (P = 0.04), gastrointestinal adverse events (P =
0.0001), musculoskeletal adverse events (P = 0.04), and mortality (P = 0.04). Greater values of PINP at baseline were
associated with greater rates of gastrointestinal adverse events (P = 0.02) at the last follow-up.
Conclusion: The present analysis supports the adoption of BMTs during pharmacological therapy setting of
patients suffering from osteoporosis.
Level of evidence: I, systematic review of RCTs
Keywords: Osteoporosis, Biomarkers, bALP, PINP, bCTx, NTx
Introduction
The management of osteoporosis represents an import-
ant therapeutic challenge for the global health system
and constitutes a considerable health expenditure [1–3].
In addition, increasing in average age [4, 5] could have a
significant impact on healthcare costs for the wide range
of drugs that are used to manage osteoporotic patients
[6–8]. Different drugs and administration methods have
been shown to be more effective than others in the pre-
vention of a certain complication or clinical outcomes
such as BMD, t-score, rate of fractures, and adverse
events [9–14]. However, prevention of complication
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along the natural history of the disease is not an easy
task to obtain [15, 16].
Biochemical markers of bone turnover (BTMs) have
gained popularity for their ability to provide specific and
dynamic indications of bone turnover mechanisms in
the delicate balance between formation and resorption
[17–19]. More precisely, serum bone alkaline phosphat-
ase (bALP) and procollagen type I N propeptide (PINP)
are considered biomarkers of bone ossification, while
serum cross-linked C-telopeptides of type I collagen
(bCTx) and urinary cross-linked N-telopeptides of type I
collagen (NTx) are considered indicators of bone resorp-
tion [17, 20, 21]. For their role in bone turnover, these
BMTs could be used as a tool for monitoring therapy in
osteoporosis [22–24]. With these assumptions, a system-
atic review has been performed to identify in these
markers a predictor role for complications in the osteo-
porotic patient, and their ability to intervene with the
most effective drug for the individual patient.
The purpose of the present study was to establish the
potential of bALP, PINP, bCTx, and NTx in predicting
the clinical outcomes in terms of BMD, t-score, rate of
fractures, and adverse events during the therapy setting
in patients with postmenopausal osteoporosis.
Material and methods
Search strategy
The present study followed the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRIS
MA) [25]. The PICOT framework was structured as
follows:
 P (problem): postmenopausal osteoporosis
 I (intervention): bALP, PINP, bCTx, and NTx
 C (control): therapy setting
 O (outcomes): BMI, fractures, adverse events
 T (timing): ≥ 6 months of follow-up
Two authors (FM;RG) independently performed the
literature search. In December 2020, the following data-
bases were accessed: PubMed, Google Scholar, Embase,
and Scopus. No time constraints were set for the data-
base search. The following keywords were used in com-
bination: osteoporosis, treatment, management, drug,
pharmacology, pharmacological, medicament, mineral,
density, bone, BMD, bone alkaline phosphatase, ALP,
procollagen type I N propeptide, PINP, serum cross-
linked C-telopeptides of type I collagen, CTx, urinary
cross-linked N-telopeptides of type I collagen, NTx, pre-
menopausal, spine, pathological, fragility, fractures, hip,
vertebral, disability, adverse events, Bisphosphonates,
Denosumab, Romosozumab, Clodronate, Raloxifene, Ter-
iparatide, Alendronate, Risedronate, Zoledronate, Iban-
dronate, Etidronate, PTH, osteoblast, osteoclast. The
resulting articles were screened by the same authors.
The full text of the articles of interest was accessed. A
cross-reference of the bibliographies was also performed.
Eligibility criteria
All randomized clinical trials (RCTs) reporting data on
biomarkers for postmenopausal osteoporosis were
accessed. According to the authors’ language capabilities,
articles in English, French, German, Italian, Portuguese,
and Spanish were eligible. Only studies of level I evi-
dence, according to the Oxford Centre of Evidence-
Based Medicine (OCEBM) [26] were considered. Articles
reporting data on patients with secondary osteoporosis
were excluded. Studies concerning patients with tumors
and/or bone metastases were also not included. Studies
reporting data on patients with iatrogenic-induced
menopausal were not included, nor those on pediatric
and/or adolescent patients. Studies regarding selected
patients undergoing immunosuppressive therapies or
organ transplantation were not considered. Studies
reporting data on combined therapies with multiple
drugs were not eligible. Studies with follow-up shorter
than 6 months were not eligible, nor were those involv-
ing less than 10 patients. Studies reporting data of com-
bined therapy with multiple anti-osteoporotic drugs
were also not included. Only articles reporting quantita-
tive data on the level of biomarkers at baseline and on
the outcomes of interest were eligible. Missing data
under these endpoints warranted the exclusion from the
present work.
Data extraction and outcomes of interests
Two authors (FM;RG) performed data extraction. Study
generalities (author, year, journal, duration of the follow-
up, daily calcium and vitamin D supplementation, treat-
ment) and patient baseline demographic information
were collected: number of samples, mean age, mean
bone mass index (BMI), mean BMD (overall, spine, hip,
femur neck), t score (spine, hip, femur), and number of
previous vertebral and non-vertebral fragility fractures.
Data concerning the following endpoints were collected
at the last follow-up: mean BMD (overall, spine, hip,
femur neck), rate of vertebral, non-vertebral, femoral,
hip fragility fractures, and body height. Data concerning
the following adverse events at the last follow-up were
collected: overall adverse events, serious adverse events
and those leading to study discontinuation, gastrointes-
tinal events, musculoskeletal events, rate of osteonecro-
sis, and mortality. Data concerning bALP, PINP, bCTx,
and NTx were extracted at baseline and last follow-up.
The outcomes of interest were to assess the association
between biomarkers and patient characteristics, bone
mass density, and adverse events at the last follow-up.
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Methodological quality assessment
The methodological quality assessment was made
through the risk of bias graph tool of the Review Man-
ager Software (The Nordic Cochrane Collaboration,
Copenhagen). The following risks of bias were evaluated:
selection, detection, performance, reporting, attrition,
and other sources of bias.
Statistical analysis
The statistical analyses were performed by the main au-
thor (FM). The IBM SPSS software version 25 was used
to assess data at baseline. Data distribution was evalu-
ated using the Shapiro–Wilk test. Normally distributed
data were evaluated using mean and standard deviation
(SD), while median and interquartile range (IQR) were
calculated for non-parametric data. The Student T-test
was used to assess significance for parametric data, while
the Mann–Whitney U-test for non-parametric variables.
Values of P < 0.05 are considered statistically significant.
Multiple linear pairwise correlations were performed to
assess associations between the value of the biomarkers
at baseline and patient demographics, bone mass density,
and adverse events at the last follow-up. The STATA
Software/MP version 16 (StataCorporation, College Sta-
tion, TX, USA) is used for the statistical analyses. A
multiple linear model regression analysis through the
Pearson product–moment correlation coefficient (r) was
used. The Cauchy–Schwarz formula was used for in-
equality: +1 is considered as positive linear correlation,
while −1 a negative one. Values of 0.1< | r | < 0.3, 0.3<
| r | < 0.5, and | r | > 0.5 were considered to have weak,
moderate, and strong correlation, respectively. The over-
all significance was assessed through the χ2 test, with
values of P < 0.05 considered statistically significant.
Fig. 1 Flow chart of the literature search
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Results
Search result
The literature search resulted in 1203 studies. Of them,
317 were duplicates. A further 757 articles were ex-
cluded because of study design (N = 221), non-clinical
studies (N = 319), secondary osteoporosis (N = 87),
small population or short follow-up (N = 15), multiple
therapies (N = 33), language limitations (N = 5), uncer-
tain results (N = 11), and others (N = 66). Another 95
articles were excluded because of data under the out-
comes of interest missing. Finally, 35 RCTs were eligible
for the present study (Fig. 1).
Methodological quality assessment
Given the exclusive inclusion of only RCTs, the risk of
selection bias was low. Most of the studies were single
and double blinded, leading to moderate-low risk of de-
tection and performance biases. Overall, the high quality
of the studies leads to a low risk of attrition and report-
ing bias. Concluding, the results of the review evaluation
about each risk of bias item for each individual included
study (Fig. 2) were low to moderate, leading to a good
assessment of the methodology.
Patient demographics
A total of 36,706 patients were included. The median
age was 67 (IQR 5), the median BMI 25.4 (IQR 1.9). The
median vertebral BMD was 0.84 (IQR 0.17), hip BMD
0.74 (IQR 0.11), and femur BMD 0.64 (IQR 0.03). The
ANOVA test found optimal within-group variance con-
cerning age, BMI, and BMDs (P > 0.1). Generalities and
patient baseline data of the included studies are shown
in detail in Table 1.
Outcomes of interest
Greater values of bALP results associated with a greater
rate of vertebral fractures (P = 0.001; r = 0.8), non-
vertebral fractures (P = 0.0001; r = 0.7), overall BMD (P
= 0.01; r = −0.8), BMD hip (P = 0.04; r = −0.5), and
BMD femur (P = 0.003; r = −0.9) at baseline. No associ-
ation with bALP at baseline and other endpoints at
follow-up was found. Greater values of NTx were associ-
ated with lower T score of the spine (P = 0.03; r = −0.7)
and of the hip (P = 0.04; r = −0.7) at baseline. Greater
values of NTx at baseline were associated with a greater
rate of adverse events at the last follow-up (P = 0.02; r =
0.9). Greater values of CTx were associated with lower
BMD spine (P = 0.04; r = −0.3), BMD hip (P = 0.01; r =
0.5), and BMD femur (P = 0.0007; r = 0.6) at baseline.
Greater values of CTx at baseline were associated with a
greater rate of adverse events leading to discontinuation
(P = 0.04; r = 0.5), gastrointestinal adverse events (P =
0.0001; r = 0.7), musculoskeletal adverse events (P =
0.04; r = 0.4), and mortality (P = 0.04; r = 0.6). Greater
values of PINP were associated with lower BMD at base-
line (P = 0.008; r = −0.4). Greater values of PINP at
baseline were associated with a greater rate of gastro-
intestinal adverse events (P = 0.02; r = 0.6) at the last
follow-up. No further statistically significant associations
were found. Table 2 shows the overall results of the
multivariate analyses.
Discussion
According to the systematic review, all BMTs analyzed
were useful to monitor the effects of pharmacological
therapy setting in postmenopausal osteoporosis. Greater
values of bALP have been associated with vertebral frac-
tures and non-vertebral fractures with overall BMD, hip
BMD, and femur BMD at baseline. Furthermore, greater
Fig. 2 Methodological quality assessment
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values of NTx were associated with lower T score of the
spine and of the hip at baseline. Greater values of NTx
at baseline were also associated to adverse events at the
last follow-up. CTx showed interesting associations, too:
greater values were associated to lower spine, hip, and
femur BMD at baseline. Greater values of this BMT at
baseline were also associated to a greater rate of adverse
events leading to discontinuation, gastrointestinal ad-
verse events, musculoskeletal adverse events, and mor-
tality. Finally, greater values of PINP were associated to
lower BMD at baseline. High values at baseline have
been associated to gastrointestinal adverse events at the
last follow-up. Because of their ability to provide infor-
mation about rapid changes in bone turnover, BMTs
have been the subject of numerous studies to investigate
their possible role in the management of osteoporotic
patients [17, 18, 27]. Bone turnover is a dynamic process
which involves bone resorption and bone formation [28,
29]. Several bone turnover markers have been
highlighted in clinical practice [27, 30, 31], although not
to necessarily identify better therapy outcomes.
Markers of bone formation and resorption have been
classified [17]. BALP and PINP are considered bone for-
mation markers [32]. BALP is a membrane-bound en-
zyme produced by osteoblasts, positively correlated with
bone formation [17, 33]. Its role in identifying the risk of
fracture has been highlighted [34] when Bjarnason et al.
first demonstrated the relationship between the modifi-
cation of the values of this BMT and the risk of fracture
[17, 33]. Statistically significant associations between
bALP levels and fracture risk have been also analyzed
showing possible association with numerous BMTs [35].
However, the association was not statistically significant,
which was not the case for osteocalcin (OC), PINP, CTx,
and NTx [35]. In a Japanese population, in contrast,
bALP did predict vertebral fractures [36]. The
Table 2 Overall results of the pairwise correlations
Endpoint bALP NTx CTx PINP
P r P r P r P r
Baseline
Vertebral fractures 0.0001 0.8 0.3 0.3 0.6 0.1 0.4 0.2
Non-vertebral fractures 0.01 0.7 0.1 0.9 0.8 −0.1 0.3 0.2
BMD 0.01 −0.8 0.5 0.4 0.1 0.5 0.008 −0.4
BMI 0.9 0.0 0.09 −0.4 0.4 −0.3 0.2 −0.2
BMD spine 0.2 −0.3 0.6 0.2 0.04 −0.3 0.5 −0.1
BMD hip 0.04 −0.5 0.9 −0.1 0.01 0.5 0.06 0.4
BMD femur 0.003 −0.9 0.2 −0.5 0.0007 0.6 0.2 0.4
T score spine 0.4 −0.3 0.03 −0.7 0.5 −0.1 0.6 0.1
T score femur 0.07 0.5 0.08 −0.8 0.09 0.3 0.5 0.1
T score hip 0.1 1.0 0.04 −0.7 0.3 0.2 0.8 0.0
Follow-up
BMD spine 0.9 0.0 0.4 0.3 0.4 0.1 0.3 0.2
BMD hip 0.2 0.3 0.9 0.1 0.3 0.2 0.3 0.2
BMD femur 0.3 0.3 0.9 0.0 0.3 0.4 0.3 0.3
Body height 1.00 −1.0 0.1 −1.0 0.1 1.0 0.1 1.0
Non-vertebral fractures 0.3 −0.3 0.1 1.0 0.4 −0.2 0.7 −0.1
Vertebral fractures 0.5 −0.2 0.7 -0.2 0.3 −0.9 0.3 0.2
Hip fractures 1.00 1.0 1.0 −1.0
Femur fractures 0.1 −1.0 0.07 −0.7 0.1 −1.0
Adverse events 0.9 0.0 0.02 0.9 0.1 0.2 0.9 0.0
Serious adverse events 0.1 −1.0 0.9 0.2 0.1 0.3 0.5 0.2
Adverse events leading to discontinuation 0.1 0.6 0.3 −0.4 0.04 0.5 0.4 0.2
Gastrointestinal adverse events 0.3 −0.6 0.3 0.3 0.0001 0.7 0.02 0.6
Musculoskeletal adverse events 0.8 −0.1 0.04 0.4 0.4 0.2
Osteonecrosis 0.9 −0.1 0.4 −0.4
Mortality 1.00 1.0 0.93 0.1 0.04 0.6 0.1 0.5
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association between bALP levels and BMD was instead
analyzed in adults with and without diabetes [37]. In
non-diabetic subjects, bALP levels were associated to
BMD [37]. On the other hand, there was no relationship
between bALP and BMD in elderly men with no history
of fractures [38]. Procollagen type 1 N-terminal propep-
tide (PINP) derives from the type 1 collagen formation
process, from its precursor, procollagen [17, 39]. It is
considered a standard indicator of bone formation [27].
Kučukalić-Selimović et al. analyzed the role of this BMT
in the bone status assessment and found a significant
negative correlation between BMD (at the femoral neck,
total hip, and lumbar spine) and serum levels of PINP
[40].
NTx and CTx are considered markers of bone resorp-
tion [17]. These two BMTs are two different forms of a
telopeptide of type I collagen, acting in the collagen deg-
radation process, and are found in serum and in urines
[41–43]. NTx showed an association with the T-score
spine and hip levels at baseline, while greater CTx values
were associated with lower spine, hip, and femur BMD
at baseline. Since they are markers of resorption, their
levels may increase in increased bone turnover, leading
to a reduction in BMD and T-score. Indeed, high bone
turnover setting (hyperthyroidism, hyperparathyroidism,
and Paget disease) is associated with greater values of
BMTs [44–49]. This has also been reported in postmen-
opausal women when a reduction of BMD may be ap-
preciable [50, 51]. Although CTx and PINP have been
recommended as the reference standard for bone resorp-
tion and bone formation [27], in the light of the results
of this systematic review, all BMTs can be statistically
related to specific complications.
This study showed several limitations, as data were
based on a large population, hence they carry a high risk
of bias. There is still little literature available about the
actual therapeutic role for these BMTs. In fact, the stud-
ies analyzed in this review did not evaluate BMTs as pri-
mary outcomes. The pathophysiology of these markers
and their relationship with osteoporosis complications
should be analyzed more specifically, as they could have
marked clinical potential. Future studies should evaluate
whether osteoporosis complication can be predicted
from variation of a given BMT, and, subsequently estab-
lish which drug could be suitable for a specific individ-
ual. These substances can be measured in serum or
urine by immunological tests [52, 53], and their levels
are influenced by endogenous and exogenous factors
[17, 19, 31, 54, 55]. As differences in sampling methods
still remain, specific research groups highlighted the
need for standardization of the collection method [27].
Another important limitation of this review is the het-
erogeneity of the studies evaluated, as they analyzed the
intervention of different types of drugs, or the same
drugs with different dosages. Furthermore, daily vitamin
D administration was not homogeneous in all studies.
Finally, future studies should consider to standardize the
measurement methods of BMTs.
Conclusion
The present systematic review shows that further studies
should validate the use of BMTs in clinical practice. Our
analysis supports the adoption of BMTs during pharma-
cological therapy setting of patients with postmeno-
pausal osteoporosis. Further studies are required to
analyze their role in predicting complications as a pri-
mary outcome.
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